Total Payments
$91,673
2024 Payments
$18,656
Companies
18
Transactions
100
Medicare Patients
10,704
Medicare Billing
$298,767
Payment Breakdown by Category
Consulting$42,616 (46.5%)
Other$36,643 (40.0%)
Research$7,180 (7.8%)
Food & Beverage$2,874 (3.1%)
Travel$2,339 (2.6%)
Education$21.24 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $42,616 | 19 | 46.5% |
| Honoraria | $17,660 | 7 | 19.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,500 | 10 | 9.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,895 | 3 | 8.6% |
| Unspecified | $7,180 | 3 | 7.8% |
| Food and Beverage | $2,874 | 41 | 3.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,588 | 4 | 2.8% |
| Travel and Lodging | $2,339 | 12 | 2.6% |
| Education | $21.24 | 1 | 0.0% |
Payments by Type
General
$84,493
97 transactions
Research
$7,180
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $32,745 | 20 | $0 (2024) |
| Abbott Laboratories | $12,999 | 35 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $10,028 | 4 | $0 (2018) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $8,000 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,123 | 12 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,309 | 2 | $0 (2021) |
| Janssen Biotech, Inc. | $5,156 | 1 | $0 (2023) |
| ABBVIE INC. | $3,000 | 1 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $2,400 | 1 | $0 (2023) |
| AstraZeneca UK Limited | $2,148 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,656 | 12 | PFIZER INC. ($11,275) |
| 2023 | $18,215 | 13 | PFIZER INC. ($7,245) |
| 2022 | $14,762 | 20 | PFIZER INC. ($6,167) |
| 2021 | $18,784 | 26 | Abbott Laboratories ($6,091) |
| 2020 | $5,838 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($3,250) |
| 2019 | $1,038 | 10 | Medtronic Vascular, Inc. ($848.28) |
| 2018 | $5,800 | 3 | Novartis Pharmaceuticals Corporation ($5,688) |
| 2017 | $8,580 | 11 | Novartis Pharmaceuticals Corporation ($4,340) |
All Payment Transactions
100 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $114.26 | General |
| 12/18/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/10/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 06/27/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 05/16/2024 | Medtronic, Inc. | PULSESELECT (Device) | Food and Beverage | In-kind items and services | $87.90 | General |
| Category: Ablation | ||||||
| 05/13/2024 | Baxter Healthcare | Hillrom - MetaNeb System (Device) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Airway Clearance Device | ||||||
| 04/08/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 03/19/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Cardiac Rhythm Management | ||||||
| 03/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,148.00 | General |
| Category: Oncology | ||||||
| 01/12/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: ONCOLOGY | ||||||
| 12/22/2023 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $945.00 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2023 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $86.53 | General |
| 09/22/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,879.50 | General |
| Category: Oncology | ||||||
| 09/08/2023 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,890.00 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2023 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 06/16/2023 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2023 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $109.43 | General |
| Category: Oncology | ||||||
| 02/23/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $5,156.04 | General |
| Category: Oncology | ||||||
| 02/16/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $76.40 | General |
| 01/31/2023 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,262.50 | General |
| Category: Oncology | ||||||
| 01/09/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| IBRANCE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 2,640 | 3,946 | $277,248 | $85,081 |
| 2022 | 10 | 2,814 | 4,275 | $220,511 | $75,502 |
| 2021 | 8 | 2,618 | 3,986 | $196,674 | $68,012 |
| 2020 | 15 | 2,632 | 3,701 | $243,279 | $70,173 |
Total Patients
10,704
Total Services
15,908
Medicare Billing
$298,767
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 1,926 | 3,058 | $91,740 | $20,112 | 21.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 84 | 84 | $37,212 | $12,330 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 117 | 142 | $23,569 | $10,165 | 43.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 75 | 86 | $22,952 | $9,517 | 41.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 89 | 109 | $18,532 | $7,856 | 42.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $15,393 | $4,808 | 31.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 37 | $10,212 | $4,228 | 41.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 31 | 31 | $10,113 | $3,232 | 32.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 21 | $12,045 | $3,023 | 25.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 38 | $7,837 | $2,496 | 31.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 23 | $6,651 | $2,272 | 34.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $8,206 | $2,271 | 27.7% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Facility | 2023 | 21 | 54 | $5,076 | $1,124 | 22.1% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 125 | 177 | $5,310 | $1,088 | 20.5% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Facility | 2023 | 19 | 19 | $1,520 | $347.04 | 22.8% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Facility | 2023 | 11 | 11 | $880.00 | $212.40 | 24.1% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 2,295 | 3,607 | $108,240 | $24,104 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 112 | 155 | $22,105 | $11,514 | 52.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 53 | 53 | $18,815 | $7,497 | 39.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 47 | 58 | $12,760 | $6,459 | 50.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 60 | 75 | $10,635 | $6,033 | 56.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 26 | 26 | $9,230 | $4,013 | 43.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 24 | 24 | $7,800 | $3,968 | 50.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 27 | 27 | $7,290 | $2,912 | 40.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 23 | $5,060 | $2,841 | 56.1% |
About Dr. Michael Fradley, MD
Dr. Michael Fradley, MD is a Cardiovascular Disease healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1427194166.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Fradley, MD has received a total of $91,673 in payments from pharmaceutical and medical device companies, with $18,656 received in 2024. These payments were reported across 100 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($42,616).
As a Medicare-enrolled provider, Fradley has provided services to 10,704 Medicare beneficiaries, totaling 15,908 services with total Medicare billing of $298,767. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Tampa, FL
- Active Since 01/29/2007
- Last Updated 11/06/2014
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1427194166
Products in Payments
- IBRANCE (Drug) $15,320
- IMBRUVICA (Drug) $11,819
- ORGOVYX (Drug) $10,417
- CALQUENCE (Drug) $8,568
- LifeVest (Device) $8,000
- KISQALI (Drug) $5,688
- Gallant CRT-D (Device) $5,071
- TASIGNA (Drug) $4,340
- BOSULIF (Drug) $3,800
- QUADRA ALLURE MP (Device) $3,500
- HeartMate (Device) $2,588
- EXKIVITY (Drug) $2,059
- HeartMate Touch (Device) $1,020
- ENSITE PRECISION (Device) $345.88
- Cardiac Mapping System (Device) $181.52
- XARELTO (Drug) $156.44
- ASSURITY (Device) $141.20
- Reveal LINQ (Device) $137.30
- WATCHMAN (Device) $123.36
- PULSESELECT (Device) $87.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Tampa
Hiram Bezerra, Md, MD
Cardiovascular Disease — Payments: $914,592
Cardiovascular Disease $914,592
Dr. James Smith, M.d, M.D
Cardiovascular Disease — Payments: $402,440
Cardiovascular Disease $402,440
Dr. David Wilson, M.d, M.D
Cardiovascular Disease — Payments: $184,907
Cardiovascular Disease $184,907
Dr. Debbie Rinde-Hoffman, M.d, M.D
Cardiovascular Disease — Payments: $92,508
Cardiovascular Disease $92,508
Bengt Herweg, Md, MD
Cardiovascular Disease — Payments: $92,301
Cardiovascular Disease $92,301
Dr. Ansel Amaral, Md, Phd, MD, PHD
Cardiovascular Disease — Payments: $90,791
Cardiovascular Disease $90,791